Agilent (A) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agilent Technologies (A) reports robust fiscal fourth-quarter results, driven by broad-based growth in all its product lines.
After reading Agilent Technologies Inc’s (NYSE:A) most recent earnings announcement (31 July 2017), I found it useful to look back at how the company has performed in the past andRead More...
Teaser: In a bid to reward its shareholders, Agilent Technologies (A) hikes dividend to 14.9 cents per share.
Patterson Companies' (PDCO) solid dental segment is a positive. The company anticipates troubles in its technology equipment business to persist through fiscal 2018.
Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk
Agilent Technologies' (A) leadership position and strength in revenue segments should aid results.
Itron's (ITRI) contract extension with SMECO anticipated to drive bookings growth in the near term.
Fujifilm (FUJIY) makes huge investment for securing TOKIWA-Bio's transgenic technology license.
Itron's (ITRI) top and bottom lines missed the Zacks Consensus Estimate in Q3 on shipment delays. The company updated its full-year 2017 guidance.
Fujifilm's (FUJIY) quarterly earnings and revenues came in higher than the respective year-ago tallies in fiscal second-quarter 2018.
Масштабные лесные пожары, обрушившиеся в начале октября на несколько районов Калифорнии (США), уничтожили историческую переписку и документацию основателей Кремниевой долины Уильяма Хьюлетта и Дэвида Паккарда. Об этой потере для всей IT-индустрии сообщает The Press Democrat.
MKS Instruments' (MKSI) Q3 performance gained traction from the benefits of its recently made business investments. The company is steadily lowering interest expenses by deleveraging balance sheet.
Amphenol Corporation (APH) lifted its revenues and earnings guidance for 2017, after reporting better-than-expected third-quarter 2017 results.
Strategic acquisitions and greater operational efficacy likely to drive Amphenol Corporation's (APH) Q3 performance. However, lingering headwinds remain a drag.
Agilent Technologies (A) continues to perform well, driven by differentiated products, new technologies, increased focus on segments and innovation strategy.
Agilent Technologies (A) has seen a nice short-term history of beating earnings estimates, and looks poised to crush analyst expectations in its next earnings report as well.
VWR's new strategically located 35,000 square foot facility in Skalice, Czech Republic looks to drive the company's business growth in the high-prospect EMEA region.
Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.